ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

Voluntary Announcement

Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Ascentage Pharma Group International (the "**Company**" or "**Ascentage Pharma**") is pleased to announce that it has received clearance from the U.S. Food and Drug Administration ("**FDA**") to initiate a Phase 3 registrational trial of lisaftoclax (APG-2575) in previously treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is another important milestone after lisaftoclax was approved by the Center for Drug Evaluation (CDE) in China for a Phase 2 registrational clinical trial in relapsed/refractory CLL/SLL (R/R CLL/SLL) patients in December 2021. Based on the most recent results, lisaftoclax reported a 98% objective response rate (ORR) in patients with R/R CLL/SLL receiving a combination of lisaftoclax and acalabrutinib. [1]

The trial, titled **GLORA** - under protocol APG2575CG301, is a global, multi-center, randomized-controlled, registrational phase 3 clinical trial designed to assess the efficacy and safety of lisaftoclax (APG-2575) in combination with a BTKi (Bruton's tyrosine kinase inhibitor) for treatment of patients with CLL/SLL who previously treated. The study will commence in the second half of 2023.

Lisaftoclax (APG-2575), a novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma, is designed to treat, and restore apoptosis in, a variety of malignancies by selectively blocking Bcl-2. More than 600 patients have been treated so far with lisaftoclax (APG-2575), including more than 300 patients with CLL/SLL. Preliminary results from clinical trials conducted as of the date of this announcement indicate that lisaftoclax (APG-2575) is a safe and effective treatment option for these patients. Lisaftoclax (APG-2575) is typically initiated with a shorter daily ramp-up schedule and reaches therapeutic dose in less than a week, as compared with other Bcl-2 inhibitors in market or in development which may require up to or more than 1 month to complete initial ramp-up. This may in turn allow lisaftoclax (APG-2575) to provide superior convenience and attains full effective dose earlier, and thus result in less overall healthcare expenditure. Lisaftoclax (APG-2575) previously received an Orphan Drug Designation (ODD) in the U.S. for CLL, as well as other indications, such as acute myeloid leukemia (AML), follicular lymphoma (FL), and multiple myeloma (MM).

CLL/SLL is the most common form of leukemia in adults, accounting for one-quarter of the leukemia cases in the West, with over 100,000 annual new cases globally. [2] Globally, there are significant unmet medical needs in the treatment of CLL/SLL. Despite significant initial responses to current first-line treatments such as immunotherapies, chemotherapies, and BTK inhibitors, relapse and drug resistance remain major clinical challenges. The disease remains incurable and patients with adverse prognostic markers commonly experience early relapses, short duration of responses and/or treatment free periods. Lisaftoclax (APG-2575) as monotherapy and in combination with BTKi has shown impressive durable responses and safety profile.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-2575 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, August 7, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.

References:

1. Matthew S. Davids, et al; Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study. Blood 2022; 140 (Supplement 1): 2326-2328. doi: https://doi.org/10.1182/blood-2022-160386

2. Yao, Y., Lin, X., Li, F. et al. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. BioMed Eng OnLine 21, 4 (2022). https://doi.org/10.1186/s12938-021-00973-6